- Tiziana Life Sciences has raised GBP0.709m via the issue of 472,938 unsecured convertible loan notes (CLNs) to certain existing investors.

Funds raised by the issue of the CLNs will be used to fund the development of the Company's clinical stage assets milciclib and foralumab, to meet the Company's ongoing liabilities in respect of licence agreements, and for general working capital purposes.

Funds have been raised on the same terms as the fundraise announced on 8th December 2015.

Story provided by